Skip to main content
Anteris Technologies Global Corp. logo

Anteris Technologies Global Corp. — Investor Relations & Filings

Ticker · AVR ISIN · US03675P1021 ASX Manufacturing
Open in API
Filings indexed 1,665 across all filing types
Latest filing 2012-11-14 Regulatory Filings
Country US United States of America
Listing ASX AVR

About Anteris Technologies Global Corp.

https://anteristech.com/

Anteris Technologies is a structural heart company focused on the development and commercialization of medical devices for heart valve disease. Its lead product is the DurAVR® Transcatheter Heart Valve (THV), a biomimetic valve designed for patients with severe aortic stenosis. The DurAVR® THV is engineered to mimic the performance of a healthy human aortic valve, aiming to restore normal, laminar blood flow. Clinical studies have shown the device delivers a favorable hemodynamic profile, characterized by low pressure gradients and a significant reduction in prosthesis-patient mismatch (PPM), even in patients with challenging anatomies. The company is advancing its technology through pivotal clinical trials to establish a new standard in transcatheter aortic valve replacement (TAVR) and improve long-term patient outcomes.

Recent filings

Filing Released Lang Actions
Allied announces successful result for Coridon's HPV vaccine 3 pages 272.6KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement from Allied Healthcare Group about successful preclinical study results for a novel HPV vaccine developed by its investment company Coridon. It contains detailed information about the study, vaccine development, and potential market impact. There are no financial statements, regulatory certifications, or references to voting results or management changes. The content is a corporate announcement of scientific and business progress rather than a financial report or regulatory filing. It does not fit categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. It is a general company announcement about a product development milestone. Therefore, the best fitting category is Regulatory Filings (RNS), which serves as a fallback for miscellaneous announcements that do not fit other specific categories.
2012-11-14 English
New contract signals strong year of sales for Allied 2 pages 254.5KB
Capital/Financing Update Classification · 85% confidence The document is an ASX announcement dated 7th November 2012, describing a new contract secured by Allied Healthcare Group for supplying an infusion management platform. It discusses sales growth, contract details, and future product launches. There are no financial statements, regulatory certifications, or detailed financial data presented. The document is a company announcement about a contract win and sales outlook, not a financial report, earnings release, or management discussion. It is also not a report publication announcement or regulatory filing as it contains substantive business update content. Therefore, the document best fits the category of Capital/Financing Update (CAP) as it relates to business growth and contract acquisition impacting company revenue prospects.
2012-11-06 English
Appendix 4C - quarterly 6 pages 434.7KB
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Appendix 4C - Quarterly Report' and is addressed as an announcement to the Australian Stock Exchange. It contains detailed financial data including consolidated cash flow statements for the quarter ended 30 September 2012, with specific line items for operating, investing, and financing cash flows. The document also includes notes on compliance with accounting standards and a company secretary's signature. The length of the document (8039 characters) and the presence of substantive financial data confirm it is a financial report rather than a brief announcement or certification. The quarterly nature and detailed financial statements align with the definition of an Interim / Quarterly Report (IR). Therefore, the correct classification is IR with high confidence. Q1 2013
2012-10-30 English
Waiver to Listing Rule 10.13.5 1 page 248.4KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement regarding a waiver granted by ASX Limited related to listing rule 10.13.5. It discusses the approval of issuing shares to directors in lieu of fees and conditions related to disclosure in the company's annual report. The document does not contain financial statements or detailed financial data, nor is it a full report. It is a regulatory announcement about a waiver and share issuance conditions. The document length is short (2899 characters), and it is clearly an announcement rather than a report. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2012-10-24 English
Change in substantial holding 2 pages 60.0KB
Regulatory Filings
2012-10-22 English
Full Annual Report to shareholders 42 pages 3.6MB
Annual Report Classification · 100% confidence The document is titled 'Annual Report 30 June 2012' and contains detailed sections typical of an annual report, including Chairman's Letter, Corporate Directory, Review of Operations, Directors' Report, Consolidated Financial Statements, Notes to the Financial Statements, Directors' Declaration, and Auditors' Declaration. It covers the full fiscal year ended 30 June 2012 and includes comprehensive financial and operational information. The length is substantial (15,000 characters), indicating it is the full report rather than a brief announcement. There is no indication that this is merely an announcement of the report or a certification. Therefore, this document fits the definition of an Annual Report (10-K). FY 2012
2012-10-18 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.